News

Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025
Q1 2025 Management View CEO Phillip Chan reported that CytoSorbents is focused on three main areas: the performance and growth catalysts of the core CytoSorb business, regulatory status and plans for ...
Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing
Discover key takeaways from Talphera's Q1 2025 Earnings Call! Learn about FDA protocol changes, financial updates, and progress on the NEPHRO CRRT study.
BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript
BioCardia, Inc. ( NASDAQ: BCDA) Q1 2025 Earnings Conference Call May 14, 2025, 16:30 PM ET Peter Altman - President and CEO David McClung - CFO Miranda Peto - IR Joe Pantginis - H.C. Wainwright Laura ...
Devdiscourse9h
Global Health Updates: Major Investments and Policy Shifts Shape the Landscape
The latest health news highlights Sanofi's $20 billion U.S. investment through 2030, Merck's cancer drug expansion and the ...
Upheaval at FDA pushes some biotech firms to move early trials out of US
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
FDA upheaval pushes some biotech firms to plan early trials out of US
The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...